IMUNON Hosts R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer

Core Insights - IMUNON, Inc. will host an R&D Day for investors on November 10, 2025, in New York City to provide updates on its pivotal Phase 3 study of IMNN-001, a DNA-mediated immunotherapy for advanced ovarian cancer [1][2] Company Overview - IMUNON is a clinical-stage biotechnology company focused on innovative treatments that utilize the body's natural mechanisms to generate effective responses against various diseases, differentiating itself from conventional therapies [4] - The company is developing non-viral DNA technology, with its first modality, TheraPlas, aimed at gene-based delivery of cytokines for solid tumors, and the second modality, PlaCCine, for gene delivery of viral antigens [4] Clinical Programs - The lead clinical program, IMNN-001, is a DNA-based immunotherapy for advanced ovarian cancer, currently in Phase 3 clinical trial (OVATION 3) after completing a Phase 2 trial (OVATION 2) [5] - IMNN-001 instructs the body to produce cancer-fighting molecules at the tumor site, aiming to provide safe and durable treatment outcomes [5] Event Details - The investor event will feature presentations from ovarian cancer experts, principal investigators from the OVATION 3 study, and statistical experts, discussing new data on IMNN-001 and its potential impact on ovarian cancer treatment [2][3] - A live Q&A session and networking opportunities will follow the formal presentations, allowing attendees to engage with speakers and IMUNON management [2] Featured Presentations - Presentations will include topics such as the potential of IMNN-001 to transform the microtumor environment, safety and tolerability insights, and statistical properties of the Phase 3 trial design [6]